Trial Profile
A Phase I Open-label Study to Evaluate Safety and Immunologic Response of COMBIG-DC Administered Intratumorally in Patients With Metastatic Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Oct 2022
Price :
$35
*
At a glance
- Drugs Ilixadencel (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Sponsors Mendus
- 03 Apr 2018 According to an Immunicum media release, has followed the surviving patients over the course of the last 5 years and as of January 18, 2018, which is the final update, three of the 12 patients were still alive.
- 09 Oct 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 18 Feb 2014 New source identified and integrated: ClinicalTrials.gov record.